Gabelli Upgrades Assertio Therapeutics (ASRT) to Buy
- S&P 500 and Dow slip as upcoming Fed meeting looms
- Oil prices rise to over two-year high as demand improves, supplies tighten
- Bitcoin (BTC) Price Pops 10% as Tesla's Musk Signals Another U-Turn on Bitcoin Payments
- Lordstown Motors (RIDE): CEO and CFO Resign, Presents Results of Investigation Of Hindenburg Research Report
- Paul Tudor Jones is 'Probably' Buying Commodities, Crypto, Gold if Fed Continues to Ignore Inflation Concerns, Endorses Bitcoin (BTC) as a Portfolio Diversifier
Gabelli analyst Kevin Kendra upgraded Assertio Therapeutics (NASDAQ: ASRT) from Hold to Buy.
Shares of Assertio Therapeutics closed at $0.59 yesterday.
You May Also Be Interested In
- UPDATE: Raymond James Upgrades EnLink Midstream, LLC (ENLC) to Outperform
- Jefferies Upgrades Kubota Corp (6326:JP) (KUBTY) to Buy
- Evercore ISI Upgrades Navigator Holdings Ltd. (NVGS) to Outperform
Create E-mail Alert Related CategoriesUpgrades
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!